<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966888</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-BIG2-04</org_study_id>
    <secondary_id>CDR0000642751</secondary_id>
    <secondary_id>ISRCTN61145589</secondary_id>
    <secondary_id>EU-20943</secondary_id>
    <nct_id>NCT00966888</nct_id>
  </id_info>
  <brief_title>Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy</brief_title>
  <official_title>Selective Use of Postoperative Radiotherapy AftEr MastectOmy - SUPREMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays or other types of radiation to kill&#xD;
      tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain&#xD;
      after surgery. It is not yet known whether radiation therapy is more effective than&#xD;
      observation after mastectomy in treating women with stage II breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it&#xD;
      works compared with standard therapy in treating women with stage II breast cancer who have&#xD;
      undergone mastectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall survival of women at intermediate risk for locoregional recurrence&#xD;
           of breast cancer treated with ipsilateral chest wall adjuvant radiotherapy after&#xD;
           mastectomy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy,&#xD;
           patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive standard of care and observation only. After completion of&#xD;
           study therapy, patients are followed up twice in the first year, and then annually for&#xD;
           up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute and late morbidity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest wall recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of death (breast cancer, or intercurrent disease [cardiovascular or non-cardiovascular])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care and observation only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Chest wall radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed unilateral invasive breast cancer&#xD;
&#xD;
               -  pT1, pN1, M0 disease&#xD;
&#xD;
               -  pT2, pN1, M0 disease&#xD;
&#xD;
               -  pT2, pN0 disease with grade III histology and/or lymphovascular invasion&#xD;
&#xD;
               -  Multifocal breast cancer meeting both of the following criteria:&#xD;
&#xD;
                    -  Largest discrete tumor ≥ 2 cm if N0&#xD;
&#xD;
                    -  Grade III histology and/or lymphovascular invasion&#xD;
&#xD;
          -  No bilateral breast cancer&#xD;
&#xD;
          -  Axillary node negative status by axillary clearance, axillary node sampling, or&#xD;
             sentinel node biopsy&#xD;
&#xD;
               -  Patients with axillary node positive (1-3 positive nodes, including&#xD;
                  micrometastases* &gt; 0.2 mm and ≤ 2 mm) must have had an axillary node clearance&#xD;
                  (minimum of 10 nodes removed) performed&#xD;
&#xD;
                    -  No more than 3 pathologically involved lymph nodes&#xD;
&#xD;
               -  No internal mammary nodes visible on sentinel node scintigraphy in the absence of&#xD;
                  negative histology NOTE: *Isolated tumor cells not counted as micrometastases&#xD;
&#xD;
          -  Underwent total mastectomy (with minimum of 1 mm margin clear of invasive cancer and&#xD;
             DCIS) and axillary surgery with staging procedure&#xD;
&#xD;
               -  Must have undergone adjuvant systemic chemotherapy if indicated for&#xD;
                  intermediate-risk breast cancer&#xD;
&#xD;
               -  Patients undergoing immediate breast reconstruction allowed&#xD;
&#xD;
          -  No known BRCA1 and BRCA2 carriers&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fit for adjuvant chemotherapy, adjuvant endocrine therapy, and post-operative&#xD;
             radiotherapy&#xD;
&#xD;
          -  No prior or concurrent malignancy except curatively treated nonmelanomatous skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent trastuzumab&#xD;
&#xD;
          -  No prior neoadjuvant systemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian H. Kunkler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh Cancer Centre at Western General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian H. Kunkler, MD</last_name>
      <phone>44-131-537-2214</phone>
      <email>i.kunkler@ed.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary - Castle</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter A. Canney, MD</last_name>
      <phone>44-141-211-1160</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

